Why One FDA/CE Clearance Opens Far Fewer CGM Markets: The Global Class-Divergence Map
A comprehensive cross-market analysis of continuous glucose monitor (CGM) classification, clinical trial requirements, and reimbursement gates across the US, EU, China, Japan, and Canada.
The Illusion of Global Leveraged Clearances in Diabetes Tech
For continuous glucose monitor (CGM) manufacturers, the global market represents a massive commercial opportunity. Driven by a global diabetes population that is projected to grow from 589 million in 2024 to 853 million by 2050 (according to the International Diabetes Federation's Diabetes Atlas, 11th edition), the global CGM market is estimated by third-party market research at roughly $12–14 billion, growing at a compound annual growth rate (CAGR) in the mid-teens.
When a diabetes-tech startup secures a U.S. FDA 510(k) clearance or an EU MDR CE mark, the initial commercial assumption is that the hardest part of the regulatory journey is complete. The clearance is frequently viewed as a global key that can be easily leveraged to unlock secondary markets across Asia-Pacific and Latin America through abridged regulatory review pathways.
In reality, CGMs do not travel well. Unlike simpler medical devices where regulatory reliance allows for rapid, low-cost registration, continuous glucose monitors face a highly fragmented global regulatory environment. As a CGM travels across borders, it encounters three significant hurdles:
- Risk Class Inflation: The identical sensor, containing the same enzyme-tipped subcutaneous wire and transmitter, is classified at progressively higher risk categories as it moves from West to East.
- US Clearance Concentration: The regulatory estate in the largest market (the U.S.) is highly concentrated among domestic oligopolies, creating a closed ecosystem that is difficult for new entrants to penetrate.
- Local Trial and Agent Requirements: Key markets like China and Japan require a domestic agent and may require local clinical data or a domestic clinical trial, alongside complex post-market surveillance.
- Reimbursement Non-Portability: Regulatory clearance is only the first gate. Reimbursement coverage is entirely national, and coverage decisions do not cross borders.
As detailed in PureGlobal's CGM global market access report, navigating these hurdles requires manufacturers to abandon the idea of a single global regulatory pathway. Instead, they must design a market-entry map that accounts for how risk classification inflates, how trial requirements shift, and how reimbursement must be secured as an independent gate.
The Eastward Class-Inflation Ladder: Market-by-Market Classification
The primary barrier to global CGM expansion is risk classification divergence. While the International Medical Device Regulators Forum (IMDRF) advocates for global harmonization, national regulatory authorities view the clinical risks associated with continuous glucose sensing through very different lenses.
The table below outlines the classification, regulatory pathway, and local clinical trial requirements for a transcutaneous CGM across five major jurisdictions:
| Jurisdiction | Regulator / Law | Risk Classification | Premarket Pathway | Local Clinical Trial Required? |
|---|---|---|---|---|
| United States | FDA / 21 CFR 862.1355 | Class II (iCGM, code QBJ) | 510(k) or De Novo | No (if using established predicate and meeting special controls) |
| European Union | Notified Bodies / EU MDR | Class IIb (Rule 11/Rule 12) | Conformity Assessment (CE Mark) | No (if clinical equivalence is demonstrated; though PMCF required) |
| Canada | Health Canada | Class III / IV | Medical Device License (MDL) | No (usually accepts FDA/CE clinical data packages) |
| Japan | PMDA / MHLW | Class III (Spec. Controlled) | Shonin Premarket Approval | Case-by-case (PMDA applies the ICH E5 ethnic-factors framework; a bridging or local study may be requested, but is not automatic for a device) |
| China | NMPA / CMDE | Class III (High Risk) | Premarket Registration | Clinical evaluation required; a domestic trial is typically expected for a novel Class III CGM unless existing clinical data (literature/predicate or accepted overseas data) is sufficient |
1. United States: The Class II iCGM Framework
In the U.S., the FDA historically regulated CGMs as Class III devices requiring a Premarket Approval (PMA). In March 2018, the FDA authorized the Dexcom G6 as an "integrated CGM" (iCGM), and in February 2022 it issued a final rule formally classifying iCGMs as Class II under 21 CFR 862.1355 (product code QBJ). This regulation includes "special controls" that define the specific analytical and clinical accuracy thresholds the device must meet. Under this framework, subsequent iCGM systems can be cleared via the relatively low-cost 510(k) pathway by demonstrating substantial equivalence to a cleared iCGM predicate.
2. European Union: The Class IIb MDR Classification
Under the EU Medical Device Regulation (EU 2017/745), CGMs are classified as Class IIb devices. Because the sensor is an invasive device intended for continuous use (greater than 30 days cumulative wear through serial sensor replacements) and monitors a critical physiological parameter where incorrect readings can lead to immediate danger (e.g., severe hypoglycemia), it does not qualify as an IVD. It is audited by a Notified Body under MDR Annex VIII. While EU MDR has tightened clinical data requirements, manufacturers can still secure a CE mark without conducting new European trials if they can demonstrate clinical equivalence to a legally marketed device.
3. Canada: Health Canada Class III/IV Divergence
Health Canada regulates CGMs under the Medical Device Regulations (SOR/98-282). Depending on the specific indications (e.g., whether the device is cleared for pediatric use or integrates with an automated insulin delivery pump), the system is classified as Class III or Class IV. Health Canada requires a Medical Device License (MDL). While the review is thorough (targeting 75 days for Class III), Canada generally accepts clinical data packages generated for FDA or CE submissions.
4. Japan: PMDA Class III Shonin Review
As a device moves to Japan, the PMDA classifies CGMs as Class III (Specially Controlled Medical Devices). Registration requires a Shonin premarket approval. A foreign manufacturer must appoint a domestic Marketing Authorization Holder (MAH) or Designated Marketing Authorization Holder (DMAH) to manage the submission. The PMDA evaluates the clinical data package under the ICH E5 "ethnic factors" framework on a case-by-case basis: because a CGM is a device (not a systemically metabolized drug), ethnic-sensitivity concerns are limited, and PMDA will often accept foreign clinical data. Where ethnic or use-practice differences cannot otherwise be addressed, PMDA may request a local bridging study or additional Japanese data — but this is a targeted request, not an automatic mandate triggered simply by the absence of East Asian cohorts.
5. China: NMPA Class III and Clinical Evaluation
The peak of risk classification is China, where the NMPA classifies all CGMs as Class III devices. The NMPA requires a domestic agent and a single registration unit submission. On clinical evidence, the governing rule is the Provisions for Medical Device Registration: NMPA requires clinical evaluation, which may be performed by (a) conducting a clinical trial, or (b) analyzing clinical literature and/or predicate-device clinical data. A new in-country clinical trial is required when the existing clinical data is insufficient to establish safety and effectiveness; for a novel Class III CGM, CMDE typically expects a domestic trial, and overseas data is accepted only where it adequately addresses the Chinese population. CMDE also publishes CGM-specific technical review guidance and maintains a clinical-evaluation exemption catalog. Separately, imported Class III devices are generally expected to be accompanied by proof of marketing authorization from the country of origin (commonly a Certificate of Free Sale — for a US-made sensor, the FDA clearance); an innovative-device "green channel" route can bypass this, and a draft Medical Device Administrative Law has proposed relaxing it, but as of mid-2026 it remains in effect.
Why Risk Classification Inflates Eastward
The phenomenon of "eastward class-inflation" is driven by two different regulatory philosophies: intended use controls versus intrinsic technical risk.
In the U.S. and Europe, regulators focus on how the device is integrated into the patient's workflow. The FDA’s iCGM classification is built around the concept of interoperability. By establishing strict special controls for accuracy and data communication, the FDA allows the device to be treated as a Class II component that can safely connect to other devices (like insulin pumps or smartwatches). The regulatory burden is shifted to ensuring compliance with these technical special controls.
Conversely, Asian regulators focus on the intrinsic safety profile of the physical device and on whether the submitted clinical data is representative of their own patient population. Because a CGM involves a transcutaneous sensor wire that remains in contact with subcutaneous tissue for 7 to 15 days, NMPA and PMDA view it as a high-risk invasive device. This is why they scrutinize whether the Western trial population and use-practice translate to their markets — and may request bridging data or a domestic trial where they conclude it does not — rather than automatically accepting or rejecting the Western package wholesale.
For a manufacturer, this means that the clinical data package used to secure an FDA 510(k) clearance—which typically relies on analytical bench testing and a single U.S.-based clinical trial—may be insufficient on its own for China (where a novel Class III CGM typically needs a domestic trial) and may need supplementation for Japan. The cost of entry into China, for example, can include designing, ethics-clearing, and executing a multi-site clinical trial under Chinese Good Clinical Practice (GCP) standards, which can add on the order of $1.5 million to $3 million and 2 to 3 years to the market access timeline.
Canada SOR/98-282: The Class III vs. Class IV Closed-Loop Elevation
For manufacturers filing in Canada, the interaction between the CGM and other active devices plays a critical role in classification. Under Health Canada SOR/98-282, a standard standalone CGM is regulated as a Class III medical device.
However, if the CGM is indicated to connect directly to an Automated Insulin Delivery (AID) or hybrid closed-loop system—where the CGM readings automatically command the pump to adjust insulin dosing—Health Canada elevates the CGM’s classification to Class IV (the highest risk class).
The impact of this up-classification is severe:
- Dossier Expansion: Class IV MDL applications require a full, comprehensive review of the design design history, including mechanical and software risk logs, material biocompatibility, and clinical data from active hybrid closed-loop studies.
- Notified Body Standards: The manufacturer must hold a valid CAN/CSA-ISO 13485 certificate under MDSAP (Medical Device Single Audit Program).
- Filing Fees and Timelines: Class IV filing fees are double those of Class III, and Health Canada's review target extends from 75 days to 90 days, though real-world reviews frequently take 12 to 15 months.
Technical Clinical Metrics: MARD and Consensus Error Grid (CEG)
To satisfy clinical evaluators at the FDA, NMPA, or Health Canada, CGM manufacturers must present statistical evidence of device performance. The three standard clinical accuracy metrics are:
- Mean Absolute Relative Difference (MARD): The average of the absolute differences between the CGM readings and the reference laboratory values, expressed as a percentage. A lower MARD indicates higher accuracy. The industry benchmark for clinical clearing is a MARD under 10%.
- Consensus Error Grid (CEG) / Parkes Error Grid: A grid divided into five zones (A, B, C, D, E) based on the clinical risk of treatment decisions made from the device readings. Zone A represents clinically correct decisions; Zone B represents acceptable decisions; Zone C represents decisions likely to lead to over- or under-treatment but with minimal danger; Zone D and E represent decisions that could lead to clinical danger. Regulators typically expect at least 95% of paired readings to fall within Zone A and B.
- Clarke Error Grid: An older grid model similar to the CEG. While still accepted, most regulators (especially CMDE in China) now prefer the Consensus Error Grid because its risk boundaries are aligned with current clinical practice.
Detailed Regulatory Timeline and Cost Comparison
To illustrate the operational differences across these markets, the table below provides an estimation of the pre-market submission fees, target review times, and typical total project duration (including clinical trials where relevant) for registering a CGM:
| Jurisdiction | Authority Filing Fee (approx.) | Target Review Timeline | Total Project Duration (estimate) | Primary Gatekeeper |
|---|---|---|---|---|
| United States | ~$26,067 (510(k) standard, FY2026 MDUFA) | 90 FDA days | 6–9 months | FDA CDRH |
| European Union | Variable Notified Body fees (~$30k-$80k) | 12–18 months | 12–24 months | Notified Body (e.g., BSI, TÜV SÜD) |
| Canada | ~$12,000 (Class III) / ~$24,000 (Class IV) | 75 days (Class III) / 90 days (Class IV) | 6–10 months (Class III) / 12–15 months (Class IV) | Health Canada |
| Japan | ~$35,000 | 9–12 months (excluding trial) | 18–36 months (with local trial) | PMDA / MHLW |
| China | ~$45,000 (registration fee) | 12–18 months (excluding trial) | 24–48 months (with mandatory trial) | NMPA / CMDE |
(Note: Authority filing fees are approximate, drawn from each regulator's published user-fee schedule effective in FY2026, and exclude consultant, local-agent, translation, notified-body, and clinical-trial costs — which represent the vast majority of the budget in Class III markets. The U.S. figure is the FY2026 FDA standard 510(k) MDUFA fee; qualifying small businesses pay roughly a quarter of the standard rate.)
China NMPA Clinical Trial Design Requirements for CGMs
Because China represents the most demanding registration pathway, it is useful to examine the clinical trial parameters that a domestic CGM trial typically involves. The figures below reflect parameters consistent with CMDE's CGM technical review guidance and the accuracy norms also used by the FDA iCGM special controls and ISO/CLSI point-of-care glucose standards; sponsors must confirm the exact requirements against the current CMDE guidance for their specific device, because they are applied case-by-case rather than as fixed universal minimums:
- Sample Size: A CGM trial commonly enrolls on the order of 100 evaluable subjects completing the full sensor wear cycle, with enrollment scaled up (often to roughly 120 to 130 patients) to account for dropouts, sensor failures, and early removal.
- Multi-Center Requirement: Trials are typically run across multiple (commonly at least 3) clinical sites in China, each a registered GCP institution.
- Reference Comparison (Venous Blood): During the wear period, subjects undergo intensive clinic days on which venous blood samples are drawn at frequent intervals (commonly about every 15 minutes across an 8 to 12 hour window) and analyzed on a laboratory-grade reference analyzer (such as the YSI 2300 Stat Plus).
- Evaluation Metrics: Accuracy is evaluated by the Mean Absolute Relative Difference (MARD) against the reference values, with performance commonly expected to land at a MARD under about 10% with a large majority (on the order of 85%+) of paired points in Zones A and B of the Consensus Error Grid (CEG).
- Pediatric Indications: If the manufacturer seeks a pediatric indication (e.g., down to 2 years of age), a separate pediatric cohort is enrolled and evaluated under a distinct protocol.
The U.S. CGM Clearance Estate: A Closed Oligopoly
To understand the competitive dynamics of entering the U.S. market, it is useful to examine the concentration of ownership within the FDA's clearance registry. Analysis of the FDA 510(k) database reveals that the U.S. CGM market is an extremely concentrated oligopoly.
An analysis of active clearances across the primary CGM product codes (including iCGM, hospital CGM, and secondary display codes: QBJ, QDK, QDL, QII, QLG, QRX, SAF, SBA, SBH, PYV, and PJT) shows a total of 45 clearances granted to 9 distinct applicants. Crucially:
- US-Held Clearances: 100% of these clearances are held by companies headquartered in the United States.
- The Dexcom-Abbott Duopoly: Together, Dexcom (24 clearances) and Abbott (12 clearances) hold 80% (36 of 45) of all clearances in this product estate.
- The Long Tail: The remaining 9 clearances are distributed among a small handful of operators: Insulet (3), Bigfoot Biomedical (2 - acquired by Abbott), Senseonics (1), Medtronic MiniMed (1), Welldoc (1), and Signos (1).
(Note: While some industry reports cite a narrower figure of 37 clearances by excluding secondary display software or specific hospital-use codes, the overarching trend remains identical: Dexcom and Abbott maintain an absolute duopoly, capturing 80% to 92% of the cleared regulatory footprint).
This high concentration of clearances has significant strategic implications. Earning an FDA clearance is not merely a technical challenge; it requires navigating a patent landscape dominated by the two market leaders.
Furthermore, the recent expansion into Over-the-Counter (OTC) consumer wellness CGMs has occurred entirely within this established estate. Rather than new entrants capturing the OTC market, the existing duopoly secured clearances for consumer-facing versions of their sensors:
- Dexcom Stelo: Cleared on March 5, 2024, as the first OTC CGM for wellness users.
- Abbott Lingo: Cleared on May 29, 2024, targeting general health and metabolic optimization.
- Abbott Libre Rio: Cleared on June 7, 2024, for Type 2 diabetics not using insulin.
All three OTC devices were cleared through the 510(k) pathway under new, specific consumer product codes, further cementing the duopoly’s control over both the clinical and consumer wellness markets in the United States. For a detailed breakdown of how safety records and adverse events are distributed across this duopoly, see our CGM recall and adverse-event patterns from MAUDE.
Reimbursement: The Second Gate That Travels Even Less Than Approval
Securing regulatory clearance or approval is only the first step toward commercial viability. For a daily-wear consumable like a CGM, the ultimate determinant of market adoption is reimbursement. However, reimbursement frameworks are national, localized, and highly fragmented.
Approval does not guarantee coverage. The table below traces the key reimbursement milestones across three major markets, demonstrating that each country made its coverage decisions years after initial regulatory clearances:
- United Kingdom (March 2022): The National Institute for Health and Care Excellence (NICE) updated its guidelines to recommend continuous glucose monitoring for all adults with Type 1 diabetes. This decision was based on local health-economic modeling demonstrating that CGM use reduced long-term NHS costs associated with DKA and vascular complications.
- Australia (1 July 2022): The Australian Government expanded the National Diabetes Services Scheme (NDSS) to provide universal CGM access to all residents with Type 1 diabetes. This required a dedicated political and economic evaluation separate from the TGA regulatory clearance process. For details on how TGA leverages foreign clearances, refer to our TGA abridged review for CE-marked devices.
- United States (16 April 2023): The Centers for Medicare & Medicaid Services (CMS) expanded Medicare coverage for CGMs, effective 16 April 2023, to include beneficiaries with Type 2 diabetes who are not on insulin but experience recurrent hypoglycemia. This change was carried out through an updated Local Coverage Determination (LCD L33822, "Glucose Monitors") and its associated policy article, alongside the related National Coverage Determination NCD 40.2 (Glucose Monitors) — not a single new "NCD 186.17" CGM determination, which does not exist. For an understanding of how NCDs differ from local coverage decisions, see our guide on how Medicare coverage determinations work.
A manufacturer entering the global market cannot assume that because Medicare or NICE covers their device, a Japanese insurer or a Canadian provincial health plan will follow suit. Each market requires a dedicated health-economic evaluation, local cost-effectiveness modeling, and negotiation with national payers.
Comparison of Australia's NDSS and UK NICE Frameworks
To demonstrate how localized these reimbursement decisions are, consider the comparison between the United Kingdom and Australia:
- UK NICE Framework: The UK NHS utilizes a centralized procurement model based on clinical evidence and cost-benefit guidelines defined by NICE. To gain reimbursement, a manufacturer must prove that their CGM reduces long-term diabetic vascular complications and clinic visit frequencies. NICE guidelines mandate that the device must connect to local clinic management software and cost below a specific national threshold.
- Australia NDSS Framework: The National Diabetes Services Scheme (NDSS) is managed by Diabetes Australia on behalf of the Department of Health. The NDSS provides subsidized or fully covered access to CGM sensors for eligible Type 1 diabetics. The decision to list a device depends on its registration with the TGA and its classification under the NDSS product categories. The department evaluates how the sensor interacts with local clinical workflows and negotiates national pricing volume contracts directly with the manufacturer, separate from the European pricing models.
Software, Cybersecurity, and Technical Standards for Global CGMs
Because CGMs are connected devices, they must comply with strict international technical and cybersecurity standards, which represent another layer of regulatory complexity. These requirements vary by risk class:
- Software Lifecycle (IEC 62304): A CGM system consists of sensor software, transmitter firmware, and mobile app code. Manufacturers must document their software development lifecycle under IEC 62304. For U.S. Class II iCGMs, this is typically classified as Class B (moderate risk) software. In China (Class III), the NMPA reviews the software design history file (DHF) under high-risk Class C guidelines, requiring extensive code review logs, validation history, and algorithmic performance data.
- Cybersecurity (FDA & EU MDR): The FDA requires all "cyberdevices" (including CGMs connecting via Bluetooth to mobile phones) to submit detailed cybersecurity files under Section 524B of the FD&C Act. This includes a Software Bill of Materials (SBOM), a vulnerability management plan, and penetration testing reports. In the EU, Notified Bodies audit these cybersecurity measures under MDR Annex I General Safety and Performance Requirements (GSPR 17) and the Cyber Resilience Act.
- Biocompatibility (ISO 10993): The subcutaneous sensor needle remains in contact with tissue for up to 15 days, classifying it as an invasive device with prolonged contact. The needle and adhesive patch must undergo complete biocompatibility testing under ISO 10993-1, including tests for cytotoxicity, sensitization, intracutaneous reactivity, and subchronic toxicity.
Post-Market Surveillance (PMS) Mismatches across Regimes
Once a CGM is launched, maintaining compliance requires navigating divergent Post-Market Surveillance (PMS) and vigilance reporting frameworks:
- United States (FDA MedWatch): Manufacturers must submit Medical Device Reports (MDRs) under 21 CFR Part 803 for deaths, serious injuries, or device malfunctions that could lead to death or serious injury. For CGMs, these malfunctions include skin burns from sensor adhesive or incorrect readings that lead to insulin overdose. Reports are published in the public MAUDE database.
- European Union (EU MDR Vigilance): Under EU MDR, vigilance reporting timelines are stricter than the U.S. Manufacturers must report any serious incident immediately, and no later than 15 days after they become aware of it (reduced to 2 days for immediate public health threats). They must also submit regular Periodic Safety Update Reports (PSURs) for Class IIb devices every 2 years, documenting post-market clinical follow-up (PMCF) survey data.
- China (NMPA Adverse Event System): China requires immediate reporting of adverse events within 24 hours for deaths, and within 15 days for other serious events. The NMPA also requires an annual post-market quality report and can mandate post-market clinical studies if safety signals emerge from domestic clinical use.
These divergent PMS channels mean a manufacturer must run a localized compliance team in each region, translating safety signals and ensuring reporting times match local laws.
A Global Market Prioritization Framework for CGM Manufacturers
To navigate this complex landscape, CGM manufacturers should adopt a three-tier market prioritization framework based on total entry cost (regulatory filing fees + clinical trial costs + reimbursement negotiation time) rather than simple geographic market size.
Tier 1: The Leverage Markets (CE Mark & Reliance Countries)
- Target Countries: EU, Australia, UK, Canada, Saudi Arabia.
- Strategy: Secure the EU MDR CE mark first. Earning this mark establishes a robust clinical evaluation report (CER) that can be used to bypass clinical trials in reliance markets.
- Next Steps: Use the CE mark to file abridged registrations via Australia's TGA (leveraging CE reliance) and Canada's MDL. Simultaneously submit NICE and NDSS health-economic dossiers using European clinical data. For an example of how a leading dual-analyte system executed its CE strategy, read about how a specific dual glucose-ketone sensor reached CE mark.
Tier 2: The Oligopoly Battlefield (United States)
- Target Country: United States.
- Strategy: Prepare for a technical and patent battle. Utilize the iCGM Class II pathway (21 CFR 862.1355) by establishing equivalence to a cleared predicate.
- Next Steps: Design clinical trials specifically to meet the FDA’s iCGM special controls for analytical precision. Ensure that your intellectual property strategy accounts for the highly concentrated patent estate held by Dexcom and Abbott.
Tier 3: The Local Trial Barrier Markets (China and East Asia)
- Target Countries: China, Japan, South Korea.
- Strategy: Treat these as long-term, high-capital projects. Do not attempt entry without local partners and dedicated funding.
- Next Steps: In China, establish a partnership with a domestic agent and plan a multi-center clinical trial that complies with NMPA GCP guidelines. For a detailed breakdown of this pathway, see our guide on the NMPA registration pathway for Class III devices. In Japan, identify a domestic Marketing Authorization Holder (MAH) and prepare for PMDA Shonin review, focusing on ethnic-bridging data.
Frequently Asked Questions
Is a CGM Class II or Class III?
It depends entirely on the country. In the United States, a CGM can be classified as Class II under the iCGM framework (21 CFR 862.1355) if it meets specific special controls. In the European Union under MDR, it is classified as Class IIb. In China, Japan, and Canada, it is regulated as a Class III (or Class IV in Canada under certain configurations) high-risk invasive device.
Does FDA 510(k) clearance let me sell a CGM in China?
No. An FDA clearance is not a leveraged route into China. Imported Class III devices generally require proof of country-of-origin marketing authorization (for a US-made sensor, the FDA clearance), and NMPA still requires a separate Class III registration submission. That submission does not get exempted from NMPA's clinical-evaluation rules: for a novel Class III CGM, CMDE typically expects a domestic clinical trial unless existing clinical data (literature, predicate, or accepted overseas data) is sufficient, and a local Chinese agent is always required.
Does CE marking or FDA clearance guarantee reimbursement abroad?
No. Reimbursement is a separate national or regional decision managed by payers (such as CMS in the US, NICE in the UK, or the NDSS in Australia). Payers conduct their own health-economic evaluations and cost-effectiveness reviews, which are completely independent of the safety and efficacy clearances granted by regulators.
What is the role of a Marketing Authorization Holder (MAH) in Japan?
In Japan, foreign manufacturers cannot hold a PMDA registration directly. They must appoint a domestic Marketing Authorization Holder (MAH). The MAH is legally responsible for releasing the device into the Japanese market, maintaining quality standards under QMS Ordinance No. 169, and managing adverse event reporting to the PMDA.
Are clinical trials in China mandatory for foreign CE-marked CGMs?
Not automatically, but in practice usually yes for a novel Class III CGM. NMPA requires clinical evaluation, which can be performed by conducting a clinical trial, by analyzing clinical literature and/or predicate-device data, or by submitting accepted overseas clinical data. A new domestic trial is required when the existing clinical data is insufficient to establish safety and effectiveness in the Chinese population — and for most novel CGMs, CMDE treats the foreign data alone as insufficient and expects a domestic multi-center trial at registered GCP sites.
Conclusion: The Reality of Diabetes Tech Access
The global expansion of continuous glucose monitoring is a study in regulatory and commercial complexity. A single FDA clearance or CE mark is not a passport to global markets; it is merely the first step on a fragmented map.
By understanding how risk classification inflates eastward, how the U.S. clearance estate is concentrated, and how reimbursement operates as a localized second gate, CGM manufacturers can build a realistic market-access strategy. Success requires recognizing that the regulatory barriers in China, Japan, and the U.S. cannot be bypassed through simple regulatory reliance—they must be planned for, funded, and navigated as distinct, local projects.
Related reading: To understand the regulatory pathway of CGM competitors, see our CGM recall and adverse-event patterns from MAUDE and read about how a specific dual glucose-ketone sensor reached CE mark. For country-specific deep-dives, see our NMPA registration pathway for Class III devices and TGA abridged review for CE-marked devices. For reimbursement mechanics, read how Medicare coverage determinations work.